BOSTON – The most highly anticipated clinical study for this year's edition of the Heart Rhythm Society annual meeting, the Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial, came up short on a couple of important statistical measures, including total mortality and disabling stroke. Still, the study was close enough to a home run to suggest more widespread use of this technology, a proposal undergirded by patients' unwillingness to deal with the side effects of antiarrhythmic drugs and a significant improvement in patient quality of life. Read More
